AN INTERVIEW WITH GSK’S CHRISTOPHER MADDOX, DIRECTOR OF SITE OPERATIONS
MOCONNECT recently interviewed GSK’s Christopher Maddox, Director of Site Operations for The Slaoui Center for Vaccines Research in Rockville. The company made news when it selected Rockville to serve as its U.S. R&D Center, furthering strengthening Montgomery County as a major player in global healthcare.
Five startups have been selected to participate in the inaugural M-1 Ventures health and fitness-focused accelerator program based at Johns Hopkins University.
Women Building Bio: the XX factor is a day long conference to recognize and learn from leading women in the bioscience industry as pioneers paving the path to success. These women have faced their own unique challenges and carved out lasting legacies.
This day will catalyze the formation of a diverse network. It is a convergence of academia and industry, men and women, researchers and innovators, professionals and decision-makers gathering together to build relationships. This day long conference provides extraordinary opportunities to exchange new ideas, highlight areas of bioscience and research opportunities, and find partners for future collaboration.
TEDCO’s 7th Annual Entrepreneur Expo will bring together all of Maryland’s entrepreneurial resources from across the state into one place, at one time.
You can expect to see 700+ of the region’s top entrepreneurs, small and large business executives, angel and venture capital investors, federal and state economic development officials, university leaders and legislators.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
A startup that spun out of research at the University of Maryland School of Medicine was acquired 18 months after forming.
ROCKVILLE, Md., Aug. 2, 2017 /PRNewswire-USNewswire/ — The Emmes Corporation today announced that it was awarded a contract from the National Institutes of Health to support pediatric clinical trials sponsored by the National Institute of Child Health and Human Development (NICHD). Valued at nearly $70 million, the 10-1/2 year contract will support the NIH’s effort to improve the labeling of drugs for pediatric use.
BETHESDA, MD. August 30, 2017 – BrainScope Company, Inc., the medical neurotechnology company which created the first FDA-cleared handheld medical device for assessment of the full spectrum of traumatic brain injury, today announced it has completed a $16 million equity financing. New investor DBL Partners joined previous backers Revolution LLC, ZG Ventures, Maryland Venture Fund and other existing and new investors in the round, which the company will use to support the commercial launch of its flagship BrainScope One medical device, as well as for continued research and development initiatives.
Gaithersburg-based immunotherapy company Altimmune Inc. announced Tuesday it plans to expand into a new headquarters, but it’s not going far.
It’s a common trope that government has a lot to learn from Silicon Valley when it comes to technology. But in cybersecurity, Washington is leading the way in many respects.